- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.09. | Osivax and KM Biologics sign deal for influenza vaccine in Japan | ||
| 09.09. | Superluminal Medicines secures $120m in Series A funding round | ||
| 06.09. | Moderna's updated Covid-19 vaccine receives positive EMA CHMP opinion | ||
| 05.09. | Novartis begins construction works at two RLT manufacturing facilities in US | ||
| 04.09. | UK MHRA grants authorisation for Moderna's updated Covid-19 vaccine | ||
| 03.09. | Skyline Therapeutics secures FDA orphan drug status for RP therapy | ||
| 02.09. | Novavax's updated Covid-19 vaccine receives FDA emergency use authorisation | ||
| 30.08. | Johnson & Johnson seeks FDA approval for generalised myasthenia gravis therapy | ||
| 29.08. | Bayer partners with NextRNA to develop lncRNA-targeting cancer therapies | ||
| 28.08. | Zuellig Pharma and Regeneron sign deal to supply Libtayo in South Korea and Taiwan | ||
| 27.08. | FDA grants orphan drug status for RedHill's opaganib for neuroblastoma | ||
| 26.08. | Moderna's RSV vaccine mRESVIA gains EC approval | ||
| 23.08. | FDA grants orphan drug status to Ractigen's RAG-18 for DMD and BMD | ||
| 22.08. | RedHill launches Talicia in UAE to treat H. pylori infection | ||
| 21.08. | GSK's B7-H3-targeted ADC receives FDA breakthrough therapy status | ||
| 20.08. | FDA grants Fast Track Designation to Arthrosi Therapeutics's AR882 for gout treatment | ||
| 19.08. | EMA validates Type II Variation application for ENHERTU for breast cancer treatment | ||
| 16.08. | Aarvik announces ADC option exercise by collaboration partner ArriVent | ||
| 14.08. | FDA grants priority review for Bavarian Nordic's chikungunya vaccine BLA | ||
| 13.08. | Persist AI and Nivagen to develop AI-driven LAI manufacturing process | ||
| 12.08. | Sandoz's Enzeevu secures FDA approval for nAMD treatment | ||
| 09.08. | Bavarian Nordic secures $156.8m US vaccine deal | ||
| 08.08. | US FDA approves Purdue Pharma's Zurnai auto-injector | ||
| 07.08. | FDA accepts Exelixis' cabozantinib sNDA for neuroendocrine tumours | ||
| 06.08. | Santen and Cloudbreak enter licence agreement for pterygium treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
